Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10309678 | 0.79 | PIK3CD (0.39) | SMN1; SMN2 | |
| SCHEMBL4550375 | 0.76 | HSD11B1 (0.44) | SMN1; SMN2HSD11B1 | |
| SCHEMBL28043269 | 0.75 | CHRNB2 (0.40) | — | |
| SCHEMBL28769745 | 0.74 | — | — | |
| SCHEMBL3415496 | 0.72 | — | — | |
| SCHEMBL14515819 | 0.72 | — | — | |
| SCHEMBL24880397 | 0.71 | GLB1 (0.33) | SMN1; SMN2HSD11B1 | |
| SCHEMBL17060525 | 0.71 | GLB1 (0.33) | SMN1; SMN2HSD11B1 | |
| SCHEMBL12371776 | 0.71 | GLB1 (0.33) | SMN1; SMN2HSD11B1 | |
| SCHEMBL24880399 | 0.71 | GLB1 (0.33) | SMN1; SMN2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394796-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | CASTANEDO GEORGETTE (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | SMN1; SMN2 2134/4885HSD11B1 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.